Spotlight On... Silicon Valley's biotech scene looks to bounce back from Theranos' 'black eye'; Population-scale Asian genome project starts; CRO forms team of ex-GSK computational biologists; and more...

When the latest batch of biotech hopefuls to emerge from Silicon Valley met earlier this month for IndieBio demo day, the usual bullishness was undercut by events elsewhere, The Guardian reports. "It sucks Theranos has given us a black eye," IndieBio founder Arvind Gupta said. Yet while the faltering performance of Theranos, the flagship of Silicon Valley's push into biotech, has dealt a blow to perceptions of the field, Gupta thinks the sector will deliver on its promises eventually. "Hype tends to precede the reality in biotech, but the reality does follow," he said. "Usually." Article

> A nonprofit unveiled plans to sequence the genomes of 100,000 Asian people. Piece

> Parexel organized some of the staffers it hired from GlaxoSmithKline ($GSK) into a genomic medicine team. Release

> Kneat raised $6.1 million, positioning it to hire 30 people to support the growth of its biopharma software business. Article

> EClinical Solutions achieved accreditation on Medidata's PRO and SDV programs. Release

> Derek Lowe dug into a paper about why technological and scientific advances have failed to boost productivity in R&D. Post

> Baylor College of Medicine published a paper on sharing cancer genomic data with participants. Paper

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.